Better diagnosis of pneumocystis in patients with weak immune systems
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new way to diagnose pneumocystis, a lung infection that can affect people with weakened immune systems. It may help find the infection faster and more accurately using samples taken from your lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- Your doctor suspects you have a lung infection called pneumocystis.
- You need a bronchoscopy (a tube into your lungs) to collect fluid or sputum for testing.
- You or your family member agree to let you be in the study.
- You have not received treatment for pneumocystis for more than 72 hours.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different antibiotics for people with pneumocystis pneumonia who cannot take the standard treatment. It aims to find the best alternative therapy.
This study compares a newer, faster lab test (BioFire FilmArray) to standard testing for identifying the germs causing lung infections in hospitalized patients. The goal is to see if the faster test helps doctors choose better antibiotics more quickly.
This trial studies a new testing method (HCAP-Pcr) for people with pneumonia caught in the hospital or other healthcare settings. Doctors will use a special lung washing procedure called bronchoalveolar lavage to quickly identify the cause of the infection, which could help guide treatment faster.
This trial tests a new imaging method to quickly find Pseudomonas aeruginosa bacteria in lung fluid, and then see how well treatment works. It aims to help doctors diagnose and treat this tough infection faster.
This study tries to find early warning markers in lung fluid collected during a bronchoscopy (a camera test of the airways). The goal is to better spot and understand lung inflammation that can happen after immune checkpoint cancer treatments.
This trial is studying the genetic type of the germ that causes Pneumocystis pneumonia (PCP) in people who have had a positive respiratory test. The goal is to better understand the infection, which may help improve treatment in the future.
Hear when a new Pneumocystis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.